Guideline Video
Guideline Resources
- Title: Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations / Stage IV Non-Small Cell Lung Cancer without Driver Alterations
- Society: American Society of Clinical Oncology
- Publish Date: July 17, 2025
- With Driver Alterations:
- Without Driver Alterations:
Video Transcription
In today’s rapid update, we’ll be going over the American Society of Clinical Oncology’s newest update on Stage IV Non-Small Cell Lung Cancer With/Without Driver Alterations
In today’s video, we’ll just be going over key elements of the 2025 update so to get the full recommendations, make sure to check it out on guidelines central dot com.
Starting with key updates on Therapy for Stage IV Non-Small Cell Lung Cancer WITHOUT Driver Alterations
- For the section, First-Line Treatment Options for Patients With Good Performance Status, Any Histology, and Any PD-L1 Expression:
- Clinicians may offer nivolumab and ipilimumab plus two cycles of platinum-based chemotherapy
- For the section, Second-Line and Subsequent Treatment Options for Patients With Good PS:
- Clinicians should offer docetaxel with or without ramucirumab if the patient has already received platinum-based chemotherapy
For key guideline updates on Therapy for Stage IV Non-Small Cell Lung Cancer WITH Driver Alterations:
- For the section, EGFR Exon 19 Deletion, Exon 21 L858R Substitution, First-Line Treatment Options:
- Clinicians may offer osimertinib with platinum doublet chemotherapy or amivantamab plus lazertinib
- For the section, NRG1 Fusion, Second-Line Treatment Options:
- Clinicians may offer zenocutuzumab
Make sure to check out the full guideline from The American Society of Clinical Oncology and other related clinical decision support tools at guidelinecentral.com.
Copyright © 2025 Guideline Central, all rights reserved.